At the European Cancer Congress (ECC) 2015, Laurence Albiges, MD, of Institut Gustave Roussy, Villejuif, France, discusses the results of clinical trials reported in patients with previously treated renal cell carcinoma: CheckMate 025, a phase 3 clinical trial of nivolumab versus everolimus; and METEOR, a phase 3 clinical trial of cabozantinib versus everolimus.
